Protagonist Therapeutics filings document formal disclosures for a biopharmaceutical company built around peptide therapeutics. Form 8-K reports furnish quarterly and annual financial results, corporate updates, Regulation FD presentations and material event exhibits tied to pipeline, collaboration and operating developments.
Proxy and annual meeting filings describe board elections, executive compensation votes, auditor ratification, equity incentive plan matters, stockholder voting results and the company's common stock voting structure. These records also frame governance, compensation and capital-related disclosures for Protagonist's Nasdaq-listed Delaware corporation.
Protagonist Therapeutics, Inc. (PTGX) CFO Asif Ali exercised options for 58,629 common shares on September 30, 2026, at four exercise prices: $38.98, $23.42, $19.19 and $12.17 per share. He sold 58,629 shares in two reported transactions: 12,595 shares at a weighted-average price of $141.77 per share and 46,034 shares at $141.78 per share. The reported common-stock acquisitions and sales were effected under a Rule 10b5-1 trading plan adopted June 30, 2026.
Protagonist Therapeutics, Inc. officer Asif Ali reported an intended Rule 144 sale of 58,629 common shares, with an aggregate market value of $8,264,930.13. The approximate sale date is September 30, 2026, and Morgan Stanley Smith Barney LLC is listed as broker.
Protagonist Therapeutics, Inc. (PTGX) reported that President and CEO Dinesh V. Patel exercised fully vested stock options for 125,000 shares of common stock at an exercise price of $21.58 per share on September 8, 9 and 10, 2026, and sold the same 125,000 shares in market or private transactions on those dates. The reported sale prices were weighted average prices of $145.87, $146.18 and $144.10 per share, respectively. All transactions were effected under a Rule 10b5-1 trading plan adopted on January 30, 2026.
Protagonist Therapeutics, Inc (PTGX) reported that President and CEO and director Dinesh V. Patel, Ph.D., made a bona fide gift transfer of 510 shares of Common Stock on September 3, 2026. The shares were gifted to relatives, and he now directly holds 522,968 shares of Protagonist Therapeutics common stock.
Protagonist Therapeutics, Inc. has a significant shareholder group led by Farallon Capital Management, L.L.C., which reports beneficial ownership of 6,433,119 Shares of common stock. This position represents 9.99% of the company’s outstanding common stock.
The Farallon-managed funds collectively hold 6,348,906 Shares plus 1,500,000 Common Stock Purchase Warrants. Due to a 9.99% Beneficial Ownership Limitation in the warrant terms, only 84,213 Shares underlying the Warrants are currently counted toward beneficial ownership, with the remaining 1,415,787 Warrants treated as not exercisable within 60 days.
Protagonist Therapeutics, Inc. President and CEO Dinesh V. Patel reported option exercises and share sales in August 2026 under a Rule 10b5-1 trading plan adopted on January 30, 2026. He exercised stock options for 100,000 shares of common stock at an exercise price of $21.58 per share and sold the resulting 100,000 shares in open-market transactions at weighted average prices of $149.11 on August 10 and $148.52 on August 11. The options exercised were fully vested and were scheduled to expire on October 11, 2026.
PTGX reports that an affiliate has filed to sell common stock under Rule 144. The planned sale covers 225,000 common shares, to be sold through J.P. Morgan Securities LLC on Nasdaq, with an aggregate market value of $33,583,500.
The filing lists 64,708,285 common shares outstanding. It also notes that 75,000 common shares were sold on 05/12/2026 for $7,508,850, and that the new shares are associated with an option exercise by the issuer, to be paid in cash.
State Street Corporation reported a passive ownership stake in Protagonist Therapeutics, Inc. common stock. It beneficially owns 3,321,554 shares, representing 5.2% of the outstanding common stock. State Street reports 0 shares with sole voting or dispositive power and 3,157,671 shares with shared voting power, while having 3,321,554 shares with shared dispositive power. Several investment management subsidiaries, including SSGA Funds Management, Inc. and State Street Global Advisors entities, are identified as the relevant investment advisers for these holdings.
Protagonist Therapeutics reported a sharp turnaround to profitability for the three and six months ended June 30, 2026, driven by collaboration economics. License and collaboration revenue reached $213.5 million in the quarter and $269.8 million year‑to‑date, largely from its Takeda rusfertide deal and a Janssen ICOTYDE milestone.
Net income was $162.8 million for the quarter and $166.6 million year‑to‑date, compared with losses in 2025, while cash, cash equivalents and marketable securities rose to about $849.5 million as of June 30, 2026. The Takeda opt‑out triggered a $200 million payment and positions Protagonist for royalties of 14–29% plus up to $775 million in sales milestones if rusfertide is approved and commercialized.
ICOTYDE received FDA approval in March 2026 for moderate‑to‑severe plaque psoriasis, earning a $50 million milestone and supporting future royalties of 6–10% and up to $580 million in additional milestones. Management expects research and development spending to increase significantly in the second half of 2026 as programs such as PN‑881, PN‑477, PN‑458 and PN‑8047 advance.
Protagonist Therapeutics reported a strong turnaround for the quarter ended June 30, 2026, driven by collaboration economics. License and collaboration revenue reached approximately $213.5 million, mainly from recognizing $192.4 million of a $200 million opt-out payment from Takeda and development services, plus earlier in 2026 a $50 million milestone from Johnson & Johnson tied to ICOTYDE’s FDA approval. Net income was about $162.8 million, compared with a loss a year earlier; diluted earnings per share were $2.29.
Cash, cash equivalents and marketable securities totaled roughly $849.5 million as of June 30, 2026, with stockholders’ equity of $841.5 million. ICOTYDE had its first full quarter of commercial sales, while rusfertide’s NDA for polycythemia vera is under FDA priority review with a PDUFA date in August 2026. The company highlighted a broad partnered and wholly owned pipeline, including the oral IL-17 antagonist PN-881 and triple agonist obesity candidate PN-477, and emphasized that expected milestones and tiered royalties of 6–10% on ICOTYDE and 14–29% on rusfertide are intended to fund ongoing R&D with no anticipated near-term equity financing.